Literature DB >> 16137184

Use of duplex PCR-CTPP methods for CYP2E1RsaI/IL-2 T-330G and IL-1B C-31T/TNF-A T-1031C polymorphisms.

Yoshiko Atsuta1, Haruya Kawase, Nobuyuki Hamajima, Kazuko Nishio, Yoshimitsu Niwa, Daisuke Tanaka, Kazuhito Yamamoto, Akiko Tamakoshi.   

Abstract

BACKGROUND: Two duplex polymerase chain reaction (PCR) with confronting two-pair primer (PCR-CTPP) methods were designed for cytochrome P450 (CYP) 2E1 RsaI and interleukin (IL-2) T-330G, and for IL-1B C-31T and tumor necrosis factor-alpha (TNF-A) T-1031C. The four polymorphisms are considered to be functional, and the three cytokines reportedly inhibit CYP2E1 expression. Many studies have reported associations between the above polymorphisms and risk of diseases including cancers and inflammatory diseases. AIM: The main objective of this study was to examine the applicability of the established PCR conditions to a real situation. PARTICIPANTS: Participants were female examinees aged from 35 to 85 years who attended health checks run by a local government in Japan.
RESULTS: The allele frequencies among 325 female health check examinees were 0.804 for CYP2E1 c1 allele, 0.668 for IL-2-330T allele, 0.554 for IL-1B-31T allele, and 0.822 for TNF-A-1031T allele. p-Values from a Hardy-Weinberg equilibrium test were 0.658, 0.955, 0.062, and 0.806, respectively. DISCUSSION: Clear DNA bands observed with electrophoresis allowed us to genotype the four polymorphisms. The genotype frequencies were within the Hardy-Weinberg equilibrium test proportions, though the p-value for IL-1B C-31T was marginal.
CONCLUSIONS: Both duplex PCR-CTPP methods may be useful tools for studies on the association between these polymorphisms and disease risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16137184     DOI: 10.1007/BF03260076

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  40 in total

1.  Cytochrome P450 2E1 polymorphism in gastric cancer in Brazil: case-control studies of Japanese Brazilians and non-Japanese Brazilians.

Authors:  I N Nishimoto; T Hanaoka; H Sugimura; K Nagura; M Ihara; X J Li; T Arai; G S Hamada; L P Kowalski; S Tsugane
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-07       Impact factor: 4.254

Review 2.  PCR-CTPP: a new genotyping technique in the era of genetic epidemiology.

Authors:  N Hamajima
Journal:  Expert Rev Mol Diagn       Date:  2001-05       Impact factor: 5.225

3.  CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan.

Authors:  A Hildesheim; L M Anderson; C J Chen; Y J Cheng; L A Brinton; A K Daly; C D Reed; I H Chen; N E Caporaso; M M Hsu; J Y Chen; J R Idle; R N Hoover; C S Yang; S K Chhabra
Journal:  J Natl Cancer Inst       Date:  1997-08-20       Impact factor: 13.506

4.  Genotype frequencies of 50 polymorphisms for 241 Japanese non-cancer patients.

Authors:  Nobuyuki Hamajima; Toshiko Saito; Keitaro Matsuo; Takashi Suzuki; Tsuneya Nakamura; Akio Matsuura; Katashi Okuma; Kazuo Tajima
Journal:  J Epidemiol       Date:  2002-05       Impact factor: 3.211

5.  Triplex polymerase chain reactions with confronting two-pair primers (PCR-CTPP) for NQO1 C609T, GSTM1 and GSTT1 polymorphisms: a convenient genotyping method.

Authors:  Haruya Kawase; Nobuyuki Hamajima; Akiko Tamakoshi; Kenji Wakai; Toshiko Saito; Kazuo Tajima
Journal:  Asian Pac J Cancer Prev       Date:  2003 Jan-Mar

6.  Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells.

Authors:  Jukka Hakkola; Yin Hu; Magnus Ingelman-Sundberg
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

7.  CYP2E1 and NQO1 genotypes, smoking and bladder cancer.

Authors:  Ji-Yeob Choi; Kyoung-Mu Lee; Soo-Hun Cho; Soo-Woong Kim; Han-Yong Choi; Sang-Yoon Lee; Hyoung-June Im; Ki Jung Yoon; Hwang Choi; Inmi Choi; Ari Hirvonen; Richard B Hayes; Daehee Kang
Journal:  Pharmacogenetics       Date:  2003-06

8.  Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping.

Authors:  N Hamajima; T Saito; K Matsuo; K Kozaki; T Takahashi; K Tajima
Journal:  Jpn J Cancer Res       Date:  2000-09

9.  Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection.

Authors:  N Hamajima; K Matsuo; T Saito; K Tajima; K Okuma; K Yamao; S Tominaga
Journal:  Jpn J Cancer Res       Date:  2001-04

10.  An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population.

Authors:  J Watanabe; J P Yang; H Eguchi; S Hayashi; K Imai; K Nakachi; K Kawajiri
Journal:  Jpn J Cancer Res       Date:  1995-03
View more
  5 in total

1.  Glutathione S-transferases T1 null genotype is associated with susceptibility to aristolochic acid nephropathy.

Authors:  Bicheng Chen; Yongheng Bai; Mei Sun; Xiaojie Ni; Yunxiu Yang; Yirong Yang; Shaoling Zheng; Feifei Xu; Shengchuan Dai
Journal:  Int Urol Nephrol       Date:  2011-11-25       Impact factor: 2.370

2.  A new PCR method: one primer amplification of PCR-CTPP products.

Authors:  Guang Yin; Yoko Mitsuda; Takayuki Ezaki; Nobuyuki Hamajima
Journal:  Mol Biotechnol       Date:  2012-10       Impact factor: 2.695

3.  Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A.

Authors:  Yoshiko Ishida; Yasuyuki Goto; Takaaki Kondo; Mio Kurata; Kazuko Nishio; Sayo Kawai; Tomo Osafune; Mariko Naito; Nobuyuki Hamajima
Journal:  Int J Med Sci       Date:  2006-09-10       Impact factor: 3.738

4.  Association between Interleukin-1B C-31T polymorphism and obesity in Japanese.

Authors:  Koji Suzuki; Takashi Inoue; Atsumi Yanagisawa; Asami Kimura; Yoshinori Ito; Nobuyuki Hamajima
Journal:  J Epidemiol       Date:  2009-04-28       Impact factor: 3.211

5.  Identification of functional tumor necrosis factor-alpha promoter variants associated with Helicobacter pylori infection in the Sudanese population: Computational approach.

Authors:  Abeer Babiker Idris; Alaa B Idris; Manal A Gumaa; Mohammed Babiker Idris; Amanda Elgoraish; Mohamed Mansour; Dalia Allam; Bashir Mo Arbab; Nazar Beirag; El-Amin M Ibrahim; Mohamed A Hassan
Journal:  World J Gastroenterol       Date:  2022-01-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.